Enhancement by Perflubron emulsion (Oxygent(R)) and carbogen breathing of the tumor growth delay of the FSaIIC fibrosarcoma after treatment with antitumor alkylating agents

Sylvia A. Holden, Beverly A. Teicher, Chul S Ha, Gulshan Ara, Terence S. Herman

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Many anticancer drugs require oxygen to be cytotoxic, or are selectively cytotoxic toward cells under oxygenated conditions. The effects of the dilute perfluorochemical emulsion Fluosol-DA with a wide variety of chemotherapeutic agents have been explored; however, it has not been possible to determine the optimal level of circulating perfluorochemical emulsion with anticancer drugs because the volume of Fluosol that may be administered in limited. Using a concentrated 90% Perflubron emulsion, Oxygent, a wide range of perfluorochemical emulsion doses have been examined in combination with melphalan, cyclophosphamide and BCNU in a murine solid tumor model. When Oxygent was administered by injection i.v. just prior to the injection of melphalan (10 mg/kg), the greatest tumor growth delays were obtained with Oxygent levels between 4 and 12 g PFC/kg. With each of these drugs the greatest tumor growth delays were obtained when the drug was prepared in the emulsion and the combination injected i.v. In each case, each dose of drug was followed by 6 h. of breathing carbogen.

Original languageEnglish (US)
Pages (from-to)895-898
Number of pages4
JournalBiomaterials, Artificial Cells, and Immobilization Biotechnology
Volume20
Issue number2-4
StatePublished - 1992
Externally publishedYes

Fingerprint

Fibrosarcoma
Alkylating Agents
Antineoplastic Agents
Emulsions
Tumors
Respiration
Growth
Melphalan
Pharmaceutical Preparations
Neoplasms
Therapeutics
Carmustine
Injections
Cyclophosphamide
carbogen
perflubron
Oxygen

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Enhancement by Perflubron emulsion (Oxygent(R)) and carbogen breathing of the tumor growth delay of the FSaIIC fibrosarcoma after treatment with antitumor alkylating agents. / Holden, Sylvia A.; Teicher, Beverly A.; Ha, Chul S; Ara, Gulshan; Herman, Terence S.

In: Biomaterials, Artificial Cells, and Immobilization Biotechnology, Vol. 20, No. 2-4, 1992, p. 895-898.

Research output: Contribution to journalArticle

@article{5b45ee08771945bda45b78940d412b8f,
title = "Enhancement by Perflubron emulsion (Oxygent(R)) and carbogen breathing of the tumor growth delay of the FSaIIC fibrosarcoma after treatment with antitumor alkylating agents",
abstract = "Many anticancer drugs require oxygen to be cytotoxic, or are selectively cytotoxic toward cells under oxygenated conditions. The effects of the dilute perfluorochemical emulsion Fluosol-DA with a wide variety of chemotherapeutic agents have been explored; however, it has not been possible to determine the optimal level of circulating perfluorochemical emulsion with anticancer drugs because the volume of Fluosol that may be administered in limited. Using a concentrated 90{\%} Perflubron emulsion, Oxygent, a wide range of perfluorochemical emulsion doses have been examined in combination with melphalan, cyclophosphamide and BCNU in a murine solid tumor model. When Oxygent was administered by injection i.v. just prior to the injection of melphalan (10 mg/kg), the greatest tumor growth delays were obtained with Oxygent levels between 4 and 12 g PFC/kg. With each of these drugs the greatest tumor growth delays were obtained when the drug was prepared in the emulsion and the combination injected i.v. In each case, each dose of drug was followed by 6 h. of breathing carbogen.",
author = "Holden, {Sylvia A.} and Teicher, {Beverly A.} and Ha, {Chul S} and Gulshan Ara and Herman, {Terence S.}",
year = "1992",
language = "English (US)",
volume = "20",
pages = "895--898",
journal = "Artificial Cells, Nanomedicine and Biotechnology",
issn = "2169-1401",
publisher = "Informa Healthcare",
number = "2-4",

}

TY - JOUR

T1 - Enhancement by Perflubron emulsion (Oxygent(R)) and carbogen breathing of the tumor growth delay of the FSaIIC fibrosarcoma after treatment with antitumor alkylating agents

AU - Holden, Sylvia A.

AU - Teicher, Beverly A.

AU - Ha, Chul S

AU - Ara, Gulshan

AU - Herman, Terence S.

PY - 1992

Y1 - 1992

N2 - Many anticancer drugs require oxygen to be cytotoxic, or are selectively cytotoxic toward cells under oxygenated conditions. The effects of the dilute perfluorochemical emulsion Fluosol-DA with a wide variety of chemotherapeutic agents have been explored; however, it has not been possible to determine the optimal level of circulating perfluorochemical emulsion with anticancer drugs because the volume of Fluosol that may be administered in limited. Using a concentrated 90% Perflubron emulsion, Oxygent, a wide range of perfluorochemical emulsion doses have been examined in combination with melphalan, cyclophosphamide and BCNU in a murine solid tumor model. When Oxygent was administered by injection i.v. just prior to the injection of melphalan (10 mg/kg), the greatest tumor growth delays were obtained with Oxygent levels between 4 and 12 g PFC/kg. With each of these drugs the greatest tumor growth delays were obtained when the drug was prepared in the emulsion and the combination injected i.v. In each case, each dose of drug was followed by 6 h. of breathing carbogen.

AB - Many anticancer drugs require oxygen to be cytotoxic, or are selectively cytotoxic toward cells under oxygenated conditions. The effects of the dilute perfluorochemical emulsion Fluosol-DA with a wide variety of chemotherapeutic agents have been explored; however, it has not been possible to determine the optimal level of circulating perfluorochemical emulsion with anticancer drugs because the volume of Fluosol that may be administered in limited. Using a concentrated 90% Perflubron emulsion, Oxygent, a wide range of perfluorochemical emulsion doses have been examined in combination with melphalan, cyclophosphamide and BCNU in a murine solid tumor model. When Oxygent was administered by injection i.v. just prior to the injection of melphalan (10 mg/kg), the greatest tumor growth delays were obtained with Oxygent levels between 4 and 12 g PFC/kg. With each of these drugs the greatest tumor growth delays were obtained when the drug was prepared in the emulsion and the combination injected i.v. In each case, each dose of drug was followed by 6 h. of breathing carbogen.

UR - http://www.scopus.com/inward/record.url?scp=0026616256&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026616256&partnerID=8YFLogxK

M3 - Article

C2 - 1391529

AN - SCOPUS:0026616256

VL - 20

SP - 895

EP - 898

JO - Artificial Cells, Nanomedicine and Biotechnology

JF - Artificial Cells, Nanomedicine and Biotechnology

SN - 2169-1401

IS - 2-4

ER -